4.6 Article

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

Journal

ACTA NEUROPATHOLOGICA
Volume 138, Issue 2, Pages 237-250

Publisher

SPRINGER
DOI: 10.1007/s00401-019-02026-8

Keywords

Alzheimer's disease; Frontotemporal dementia; Dementia with Lewy bodies; Progressive supranuclear palsy; Parkinson's disease; Amyotrophic lateral sclerosis; Multiple sclerosis; Neurodegenerative disease; Longevity; PLCG2; Phospholipase C Gamma 2

Funding

  1. Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam
  2. Stichting Alzheimer Nederland [WE09.2014-03]
  3. Stichting VUmc fonds
  4. Stichting Dioraphte [JPco-fuND FP-829-029, 733051061]
  5. Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW) [733050814]
  6. Stichting VUmc Fonds [JPco-fuND FP-829-029, 733051061]
  7. German Study on Ageing, Cognition and Dementia in Primary Care Patients
  8. German Research Network on Degenerative Dementia
  9. Health Service Research Initiative
  10. (AgeQualiDe) - German Federal Ministry of Education and Research [KND: 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434, KNDD: 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716, 01GY1322A, 01GY1322B, 01GY1322C, 01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G]
  11. Innovative Medicines Initiative 2 Joint Undertaking [115975]
  12. UK Medical Research Council [13044]
  13. UK NIHR
  14. Medical Research Council Mitochondrial Biology Unit [MC_UU_00015/9]
  15. National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust
  16. University of Cambridge
  17. National Program for Research Infrastructure [09-063256]
  18. Danish Agency for Science Technology and Innovation
  19. Velux Foundation
  20. US National Institute of Health [P01 AG08761]
  21. Danish Agency for Science, Technology and Innovation/The Danish Council for Independent Research [11-107308]
  22. European Union [259679]
  23. INTERREG 4 A programme Syddanmark-Schleswig-K.E.R.N.
  24. EU
  25. (European Regional Development Fund)
  26. CERA Foundation (Lyon)
  27. AXA Research Fund
  28. Health Foundation (Helsefonden), Copenhagen, Denmark
  29. Danish Obesity Research Centre (DanORC)
  30. MRC centre for Causal Analyses in Translational Epidemiology (MRC CAiTE) - Wellcome Trust [WT 084762]
  31. GOYA
  32. Danish National Research Foundation
  33. Pharmacy Foundation
  34. Egmont Foundation
  35. March of Dimes Birth Defects Foundation
  36. Augustinus Foundation
  37. Health Foundation
  38. Fundacio ACE (FACE)
  39. Fundacio ACE research programs
  40. Fundacio ACE collaborates with the Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED, Spain)
  41. EU/EFPIA Innovative Medicines Initiative Joint Undertaking ADAPTED [115975, PI13/02434, PI16/01861]
  42. Accion Estrategica en Salud, integrated in the Spanish National R + D + I Plan
  43. ISCIII (Instituto de Salud Carlos III)-Subdireccion General de Evaluacion
  44. Fondo Europeo de Desarrollo Regional (FEDER-Una manera de Hacer Europa)
  45. Fundacion bancaria La Caixa
  46. Genetics of Healthy Ageing Study (GEHA - NL)
  47. EU GEHA Project [LSHM-CT-2004-503-270]
  48. Stena Foundation
  49. Swedish Research Council [2015-02830, 2013-8717]
  50. Swedish Research Council for Health, Working Life and Wellfare [2013-1202, 2005-0762, 2008-1210, 2013-2300, 2013-2496, 2013-0475]
  51. Brain Foundation
  52. Sahlgrenska University Hospital (ALF)
  53. Alzheimer's Association [IIRG-03-6168]
  54. Alzheimer's Association Zenith Award [ZEN-01-3151]
  55. Eivind och Elsa K: son Sylvans Stiftelse
  56. Swedish Alzheimer Foundation
  57. IPDGC (The International Parkinson Disease Genomics Consortium)
  58. Kompetenznetz Multiple Sklerose (KKNMS)
  59. German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS) [01GI0916, 01GI0917]
  60. Munich Cluster for Systems Neurology (SyNergy)
  61. BMBF through the Integrated Network IntegraMent, under the auspices of the e: Med Programme [01ZX1614J]
  62. EU Horizon 2020 project MultipleMS
  63. Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care
  64. Innovation-Oriented Research Program on Genomics [SenterNovem IGE05007]
  65. Netherlands Consortium for Healthy Ageing [050-060-810]
  66. Georg Forster Research Award (Alexander von Humboldt Foundation)
  67. Mayo Clinic AD
  68. National Institute on Aging [ZIA-NS003154, Z01-AG000949]
  69. National Institute of Neurological Disorders and Stroke [R01 NS080820, P50 NS072187]
  70. Mayo Clinic is a Lewy Body Dementia Association (LBDA) Research Center of Excellence
  71. American Parkinson Disease Association (APDA) Information and Referral Center [U54-NS100693]
  72. Little Family Foundation
  73. Mangurian Foundation
  74. NINDS [R01 NS078086]
  75. Mayo Clinic Center for Regenerative Medicine, Mayo Clinic Center for Individualized Medicine, Mayo Clinic Neuroscience Focused Research Team (Cecilia and Dan Carmichael Family Foundation)
  76. James C. and Sarah K. Kennedy Fund
  77. Sol Goldman Charitable Trust
  78. CurePSP| Society
  79. Tau Consortium
  80. National Institutes of Health [U19-AG03365, P50 NS38377, P50-AG005146]
  81. Johns Hopkins Morris K. Udall Center of Excellence for Parkinson's Disease Research [NIH P50 NS38377]
  82. Johns Hopkins Alzheimer's Disease Research Center
  83. NIMH
  84. NINDS Human Genetics Resource Center DNA
  85. Virginia Commonwealth University Brain Bank
  86. Georgetown University Brain Bank
  87. University of Miami
  88. Intramural Research Program of the NIH National Institute of Neurological Disorders and Stroke
  89. Fondo de Investigaciones Sanitarias-Fondos FEDER EuropeanUnion [PI15/00878]
  90. CIBERNED
  91. Carlos III Institute of Health, Spain [PI08/0139, PI12/02288, PI16/01652]
  92. Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa
  93. ALS Foundation Netherlands
  94. MND association (UK) - Generalitat de Catalunya [2017 SGR 547]
  95. Institute of Health Carlos III-Subdireccion General de Evaluacion
  96. Fondo Europeo de Desarrollo Regional (FEDER- Una manera de Hacer Europa) [PI11/02526, PI14/01126, PI17/01019, PI17/01895]
  97. Centro de Investigacion Biomedica en Red Enfermedades Neurodegenerativas programme
  98. Alzheimer Disease
  99. Fundacio Bancaria Obra Social La Caixa (DABNI project)
  100. Fundacion BBVA
  101. Biodonostia HRI Genomics Platform
  102. Fundacion Salud [PI2013156]
  103. Diputacion Foral de Gipuzkoa [114/17]
  104. Netherlands Organization for Scientific Research [NWO VICI 453-14-005, NWO: 480-05-003]
  105. VU University, Amsterdam, The Netherlands
  106. Dutch Brain Foundation
  107. Dutch National Computing and Networking Services SurfSARA [16406]
  108. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003154] Funding Source: NIH RePORTER
  109. NATIONAL INSTITUTE ON AGING [ZIAAG000936] Funding Source: NIH RePORTER
  110. MRC [MC_UU_00015/9, G1100540, MC_UU_00015/8, G0900580] Funding Source: UKRI

Ask authors/readers for more resources

The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLC gamma 2 pathway as drug-target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available